Join

Compare · OMIC vs PKI

OMIC vs PKI

Side-by-side comparison of Singular Genomics Systems Inc. (OMIC) and PerkinElmer Inc. (PKI): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both OMIC and PKI operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
  • PKI is the larger of the two at $21.38B, about 43.8x OMIC ($487.8M).
  • PKI has more recent analyst coverage (17 ratings vs 5 for OMIC).
MetricOMICPKI
Company
Singular Genomics Systems Inc.
PerkinElmer Inc.
Price
$19.98+0.35%
$115.23-0.88%
Market cap
$487.8M
$21.38B
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Laboratory Analytical Instruments
Exchange
NASDAQ
NYSE
IPO
2021
News (4w)
0
0
Recent ratings
5
17
OMIC

Singular Genomics Systems Inc.

Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. It manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits; and offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution. The company was incorporated in 2016 and is headquartered in La Jolla, California.

PKI

PerkinElmer Inc.

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Latest OMIC

Latest PKI